Filing Flows › CytomX Therapeutics (CTMX) › Q4 2025
CytomX Therapeutics (CTMX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 16, 2026
CytomX Therapeutics (CTMX) reported revenue of $663K for the fourth quarter 2025 (Q4 2025), -98% from a year earlier and -89% from the quarter before.
CytomX Therapeutics, Q4 2025: revenue $663K (-98% year over year), net loss $26.5M, operating cash flow −$23.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $663K | -89% | -98% |
| Operating profit | −$27.9M | — | — |
| Net earnings | −$26.5M | — | — |
| Operating cash flow | −$23.2M | — | — |
What changed
Revenue was $663K in Q4 2025, down 98% year over year and down 89% from the previous quarter.
Operating costs exceeded revenue by $27.9M, an operating margin of -4213.0%. Total costs grew 40% against a revenue fall of 98%. The fastest-growing cost line was Research & development (+44%). The quarter ended with a net loss of $26.5M, wider than the previous quarter's $14.2M loss.
Operating cash flow was −$23.2M. Non-cash charges added back $1.5M of share-based compensation. Working capital and other items added $1.8M. Capital expenditures of $201K exceeded it, leaving free cash flow of −$23.4M.
Questions
What was CytomX Therapeutics' revenue in the fourth quarter 2025?
CytomX Therapeutics (CTMX) reported revenue of $663K for the fourth quarter 2025 (Q4 2025), -98% from a year earlier and -89% from the quarter before.